Limits...
Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction.

Benitez Del Castillo JM, Kaercher T, Mansour K, Wylegala E, Dua H - Clin Ophthalmol (2014)

Bottom Line: Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life.Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session.No safety or tolerability issues were identified.

View Article: PubMed Central - PubMed

Affiliation: Universidad Complutense, Madrid, Spain.

ABSTRACT
Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life. Eyelid hygiene is the mainstay of treatment but is unstandardized and requires commitment from the patient and encouragement from the ophthalmologist. Blephasteam(®) is an eyelid warming device designed to be an easy-to-use and standardized treatment for MGD. In the present study, 73 patients were treated for 21 days with twice daily Blephasteam(®) sessions. The primary efficacy variable, a symptomatology visual analog scale score, declined from 63.07±21.23 (mean ± standard deviation) on day 0 to 41.90±25.49 on day 21. There were also improvements in a number of secondary efficacy variables including subjective ocular symptoms and clinical signs and symptoms of MGD and dry eye, though tear film breakup time and tear osmolarity were not improved. Global efficacy was assessed as satisfactory or very satisfactory in 83.8% of cases. Patient-reported subjective ocular symptoms declined during the study, and a majority of patients rated the efficacy of Blephasteam(®) as satisfactory or very satisfactory. Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session. No safety or tolerability issues were identified.

No MeSH data available.


Related in: MedlinePlus

Subjective ocular symptoms when getting up in the morning, before the Blephasteam® session – patients with no disturbing symptoms.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4199825&req=5

f9-opth-8-2019: Subjective ocular symptoms when getting up in the morning, before the Blephasteam® session – patients with no disturbing symptoms.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.

Mentions: Subjective ocular symptoms when getting up in the morning/ before the Blephasteam® session showed a clear tendency to diminish over the course of the study. The proportion of patients without disturbing symptoms increased from day 0 to day 20 (Figure 9).


Evaluation of the efficacy, safety, and acceptability of an eyelid warming device for the treatment of meibomian gland dysfunction.

Benitez Del Castillo JM, Kaercher T, Mansour K, Wylegala E, Dua H - Clin Ophthalmol (2014)

Subjective ocular symptoms when getting up in the morning, before the Blephasteam® session – patients with no disturbing symptoms.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4199825&req=5

f9-opth-8-2019: Subjective ocular symptoms when getting up in the morning, before the Blephasteam® session – patients with no disturbing symptoms.Note: Blephasteam®; Laboratoires Thea, Clermont-Ferrand, France.
Mentions: Subjective ocular symptoms when getting up in the morning/ before the Blephasteam® session showed a clear tendency to diminish over the course of the study. The proportion of patients without disturbing symptoms increased from day 0 to day 20 (Figure 9).

Bottom Line: Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life.Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session.No safety or tolerability issues were identified.

View Article: PubMed Central - PubMed

Affiliation: Universidad Complutense, Madrid, Spain.

ABSTRACT
Meibomian gland dysfunction (MGD) is widespread and has significant impact on patients' quality of life. Eyelid hygiene is the mainstay of treatment but is unstandardized and requires commitment from the patient and encouragement from the ophthalmologist. Blephasteam(®) is an eyelid warming device designed to be an easy-to-use and standardized treatment for MGD. In the present study, 73 patients were treated for 21 days with twice daily Blephasteam(®) sessions. The primary efficacy variable, a symptomatology visual analog scale score, declined from 63.07±21.23 (mean ± standard deviation) on day 0 to 41.90±25.49 on day 21. There were also improvements in a number of secondary efficacy variables including subjective ocular symptoms and clinical signs and symptoms of MGD and dry eye, though tear film breakup time and tear osmolarity were not improved. Global efficacy was assessed as satisfactory or very satisfactory in 83.8% of cases. Patient-reported subjective ocular symptoms declined during the study, and a majority of patients rated the efficacy of Blephasteam(®) as satisfactory or very satisfactory. Most patients found the device comfortable and were able to continue with normal activities (reading, watching TV, using a computer) during the Blephasteam(®) session. No safety or tolerability issues were identified.

No MeSH data available.


Related in: MedlinePlus